Literature DB >> 3144329

Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.

J K Cruickshank1, N M Anderson, J Wadsworth, S M Young, E Jepson.   

Abstract

STUDY
OBJECTIVE: To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure.
DESIGN: Double blind, placebo controlled, random order crossover trial with four week placebo run in period and two six week active phases separated by a two week placebo washout period.
SETTING: Outpatient department of a general hospital in a multiethnic health department. Patients--Diabetic patients with hypertension. Four dropped out before randomisation; 25 black and 14 white patients completed the trial.
INTERVENTIONS: Patients given slow release verapamil 120 mg or 240 mg twice daily with placebo or metoprolol 50 mg or 100 mg twice daily with placebo. Treatment for diabetes (diet alone or with oral hypoglycaemic drugs) remained unchanged. END POINT: Comparison of changes in blood pressure in the two groups taking both drugs.
MEASUREMENTS AND MAIN RESULTS: Metoprolol had little effect on blood pressure in black patients (mean fall 4.0 mm Hg systolic (95% confidence interval -2.5 to 10.4 mm Hg), 4.3 mm Hg diastolic (-0.8 to 9.5)) but more effect in white patients (mean falls 13.4 mm Hg (0.1 to 26.7) and 10.6 mm Hg (4.5 to 16.7) respectively). Verapamil was more effective in both groups, with mean falls of 8.8 mm Hg (2.4 to 15.0) and 8.1 mm Hg (5.0 to 11.2) in black patients and 19.1 mm Hg (5.4 to 32.9) and 11.4 mm Hg (0.9 to 22.0) in white patients. Heart fate fell significantly in black patients taking metoprolol, which suggested compliance with treatment. Metabolic variables were unaltered by either treatment. Plasma renin activity was low in both groups after metoprolol treatment, but change in blood pressure could not be predicted from baseline plasma renin activity. Urinary albumin:creatinine ratio was independently related to baseline blood pressure but not significantly changed by treatment.
CONCLUSIONS: beta Blockers alone are not effective in treating hypertension in black diabetics. Verapamil is effective but less so than in white patients. As yet no ideal monotherapy exists for hypertension in black patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144329      PMCID: PMC1835009          DOI: 10.1136/bmj.297.6657.1155

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

1.  Inverse relationship in Jamaica between plasma high-density lipoprotein cholesterol concentration and coronary-disease risk as predicted by multiple risk-factor status.

Authors:  G J Miller; N E Miller; M T Ashcroft
Journal:  Clin Sci Mol Med       Date:  1976-11

2.  Blood pressure, smoking, obesity and alcohol consumption in black and white patients in general practice.

Authors:  A P Haines; A Booroff; E Goldenberg; P Morgan; M Singh; P Wallace
Journal:  J Hum Hypertens       Date:  1987-06       Impact factor: 3.012

Review 3.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

4.  Treatment of Jamaican hypertensives with atenolol and chlorthalidone.

Authors:  G A Grell; G A Alleyne; H M Robinson; M Anderson
Journal:  West Indian Med J       Date:  1981-09       Impact factor: 0.171

5.  Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients.

Authors:  M Moser; J Lunn
Journal:  Angiology       Date:  1981-08       Impact factor: 3.619

6.  Heart attack, stroke, diabetes, and hypertension in West Indians, Asians, and whites in Birmingham, England.

Authors:  J K Cruickshank; D G Beevers; V L Osbourne; R A Haynes; J C Corlett; S Selby
Journal:  Br Med J       Date:  1980-10-25

7.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

Review 8.  Diabetes and arterial hypertension.

Authors:  P L Drury
Journal:  Diabetologia       Date:  1983-01       Impact factor: 10.122

9.  Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus.

Authors:  D E Andersson; S Röjdmark
Journal:  Acta Med Scand       Date:  1981

10.  Racial differences of parameters associated with blood pressure levels in children--the Bogalusa heart study.

Authors:  G S Berenson; A W Voors; L S Webber; E R Dalferes; D W Harsha
Journal:  Metabolism       Date:  1979-12       Impact factor: 8.694

View more
  11 in total

Review 1.  Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?

Authors:  F Dunne; M J Kendall; U Martin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  The effect of sustained release verapamil on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.

Authors:  J Lyngsøe; M Sørensen; H Sjøstrand; H Sengeløv; M T Thrane; J Holst
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 4.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 6.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

7.  Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

Authors:  L Corea; M Bentivoglio; S Berioli; C Bianchini; K Savino; M Sardina
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

8.  Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.

Authors:  T Baba; T Kodama; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus.

Authors:  M Busch Sørensen; H Sjøstrand; H Sengeløv; M Tiefenthal Thrane; J Juul Holst; J Lyngsøe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.

Authors:  C Ferrier; P Ferrari; P Weidmann; U Keller; C Beretta-Piccoli; W F Riesen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.